Abivax (ABVX) Competitors $91.77 +5.26 (+6.08%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVX vs. BNTX, TEVA, GMAB, SMMT, ASND, VTRS, RDY, MRNA, ROIV, and QGENShould you be buying Abivax stock or one of its competitors? The main competitors of Abivax include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Roivant Sciences (ROIV), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Abivax vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories Moderna Roivant Sciences Qiagen BioNTech (NASDAQ:BNTX) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Do analysts recommend BNTX or ABVX? BioNTech currently has a consensus target price of $134.46, suggesting a potential upside of 27.16%. Abivax has a consensus target price of $103.29, suggesting a potential upside of 12.54%. Given BioNTech's higher possible upside, research analysts clearly believe BioNTech is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioNTech 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64Abivax 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Which has more risk and volatility, BNTX or ABVX? BioNTech has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Abivax has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Is BNTX or ABVX more profitable? Abivax has a net margin of 0.00% compared to BioNTech's net margin of -12.20%. Abivax's return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets BioNTech-12.20% -1.84% -1.59% Abivax N/A N/A N/A Which has higher valuation and earnings, BNTX or ABVX? Abivax has lower revenue, but higher earnings than BioNTech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioNTech$2.98B8.54-$719.92M-$1.60-66.09AbivaxN/AN/A-$190.71MN/AN/A Do insiders and institutionals have more ownership in BNTX or ABVX? 15.5% of BioNTech shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to BNTX or ABVX? In the previous week, Abivax had 11 more articles in the media than BioNTech. MarketBeat recorded 18 mentions for Abivax and 7 mentions for BioNTech. BioNTech's average media sentiment score of 1.20 beat Abivax's score of 0.54 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 3 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAbivax beats BioNTech on 8 of the 14 factors compared between the two stocks. Get Abivax News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVX vs. The Competition Export to ExcelMetricAbivaxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.89B$3.38B$6.13B$10.61BDividend YieldN/A2.28%5.69%4.71%P/E RatioN/A21.9385.8627.54Price / SalesN/A274.32540.53202.58Price / CashN/A47.1237.9261.55Price / Book133.0110.2012.986.78Net Income-$190.71M-$52.40M$3.30B$275.79M7 Day Performance10.74%6.22%4.73%2.99%1 Month Performance2.83%15.91%9.96%9.50%1 Year Performance891.08%31.98%84.61%35.97% Abivax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVXAbivax2.9216 of 5 stars$91.77+6.1%$103.29+12.5%+847.5%$6.89BN/A0.0061Analyst ForecastAnalyst RevisionBNTXBioNTech2.6579 of 5 stars$105.16-0.3%$134.46+27.9%-11.7%$25.36B$2.98B-65.726,772Positive NewsTEVATeva Pharmaceutical Industries3.1669 of 5 stars$19.99-0.1%$25.57+27.9%+15.3%$22.95B$16.54B-124.9436,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.3488 of 5 stars$33.31-0.7%$40.80+22.5%+38.8%$21.55B$3.12B16.742,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.1711 of 5 stars$22.15+3.4%$31.29+41.2%+18.5%$15.92B$700K-21.93110Analyst ForecastASNDAscendis Pharma A/S3.0462 of 5 stars$210.83+3.3%$244.36+15.9%+59.1%$12.59B$393.54M-40.861,017News CoverageAnalyst ForecastHigh Trading VolumeVTRSViatris1.685 of 5 stars$10.13-0.6%$10.40+2.7%-11.9%$11.88B$14.74B-3.4932,000Analyst ForecastRDYDr. Reddy's Laboratories3.2588 of 5 stars$14.12-0.3%$16.95+20.0%-11.1%$11.82B$3.81B21.3927,811News CoveragePositive NewsAnalyst ForecastMRNAModerna4.3205 of 5 stars$27.54-3.3%$41.81+51.8%-52.2%$11.08B$3.24B-3.665,800Analyst ForecastROIVRoivant Sciences3.6509 of 5 stars$16.26+0.6%$19.94+22.6%+42.1%$11.04B$29.05M-23.23860Analyst ForecastInsider TradeQGENQiagen4.3702 of 5 stars$46.99+0.4%$49.40+5.1%+12.8%$10.40B$1.98B27.765,765Analyst Forecast Related Companies and Tools Related Companies BNTX Competitors TEVA Competitors GMAB Competitors SMMT Competitors ASND Competitors VTRS Competitors RDY Competitors MRNA Competitors ROIV Competitors QGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abivax SA Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Abivax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
